Search
Opicapone
go.drugbank.com/drugs/DB11632ApprovedInvestigationalOpicapone was approved for use by the European Commission in June 2016 [L2339] and the FDA in April 2020.[L13772] It is marketed under the brand name Ongentys as once-daily oral capsules. … of these symptoms through the use of a dopamine agonist, a monoamine oxidase B inhibitor (selegiline, rasagiline), a _catechol-O-methyl transferase (COMT)_ inhibitor, or amantadine, or using a modified-release
Tremelimumab
go.drugbank.com/drugs/DB11771ApprovedInvestigationalCTLA-4 is a cell surface receptor expressed on activated T cells to act as a negative regulator for T cells. … Tremelimumab, formerly known as ticilimumab, is a fully human IgG2 monoclonal antibody directed against cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4).
Pozelimab
go.drugbank.com/drugs/DB15218ApprovedInvestigational[A261120] Pozelimab is a human, monoclonal immunoglobulin G4<sup>P</sup> antibody against the terminal complement protein C5. … [L47850] In August 18, 2023, pozelimab was approved by the FDA for the treatment of CHAPLE disease. It is currently the only treatment explicitly indicated for CHAPLE disease.[L47875]
Acarbose
go.drugbank.com/drugs/DB00284ApprovedInvestigationalAcarbose is a complex oligosaccharide that acts as an inhibitor of several enzymes responsible for the breakdown of complex carbohydrates in the intestines. … [L31628,L31633] Acarbose is one of only two approved alpha-glucosidase inhibitors (the other being [miglitol]), receiving its first FDA approval in 1995 under the brand name Precose (since discontinued
Products: ACARBOSIO DOC GENERICIScopolamine
go.drugbank.com/drugs/DB00747ApprovedInvestigational[A228773, L31578] Scopolamine was first approved by the FDA on December 31, 1979, and is currently available as both oral tablets and a transdermal delivery system.[L31578] … [A228758, L31578] Due to its dose-dependent adverse effects, scopolamine was the first drug to be offered commercially as a transdermal delivery system, Scopoderm TTS®, in 1981.
Motixafortide
go.drugbank.com/drugs/DB14939ApprovedInvestigationalMotixafortide is a cyclic peptide hematopoietic stem cell mobilizer used to improve stem cell collection prior to autologous transplantation. … [L48136] Similar in mechanism to the previously approved [plerixafor], motixafortide is an inhibitor of C-X-C Motif Chemokine Receptor 4 (CXCR4), a protein that helps to anchor stem cells to bone marrow
Atorvastatin
go.drugbank.com/drugs/DB01076ApprovedInvestigational[A181397, A181403] Atorvastatin was first synthesized in 1985 by Dr. Bruce Roth and approved by the FDA in 1996. … Atorvastatin (Lipitor®), is a lipid-lowering drug included in the statin class of medications.
Mixtures: TIAZOMET ® A 40/10 TABLETASProducts: VIATOR-A, BACATOseltamivir
go.drugbank.com/drugs/DB00198ApprovedInvestigationalNotably, in 2017, the World Health Organization downgraded oseltamivir from its essential medicines list from a "core" drug to a "complementary" drug, due to limited cost-effectiveness. … [L7264] The benefits of oseltamivir use are controversial; a 2014 Cochrane Review of the evidence found that oseltamivir treatment had limited benefit.
Omapatrilat
go.drugbank.com/drugs/DB00886ExperimentalThis drug from BMS was not approved by the FDA due to angioedema safety concerns.
SO-101
go.drugbank.com/drugs/DB05345ExperimentalDoxepin has been prescribed for more than 40 years for the treatment of depression and anxiety at dosages typically ranging from 75 mg to 300 mg per day. … SO-101(Silenor) is a low-dose oral tablet formulation of doxepin hydrochloride that is patent protected for its use in insomnia.